The global personalized cancer vaccine market size was calculated at USD 208.35 million in 2024 and is projected to grow from USD 301.90 million in 2025 to nearly reaching USD 8,501.14 million by 2034, growing at an impressive CAGR of 44.9% between 2025 and 2034, a study published by Vision Research Reports.
The market growth is driven by major advancements in genomic technology, bioinformatics, and the effectiveness of new platforms like messenger RNA (mRNA).
Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.
Preview the Report Before You Buy – Get
Sample Pages 👉
https://www.visionresearchreports.com/report/sample/41670
What is Personalized Cancer Vaccine?
A personalized cancer vaccine is a form of immunotherapy created specifically for a patient to address the distinct mutations present in their tumor. These vaccines are frequently created using advanced technologies such as next-generation sequencing (NGS), artificial intelligence, and mRNA platforms. Customized vaccines exhibit significant promise in the treatment of cancers including melanoma, non-small cell lung cancer, and glioblastoma. In contrast to traditional therapies that provide wide-ranging effects, personalized cancer vaccines employ specific tumor neoantigens, mutations unique to a person's cancer, to stimulate a more targeted immune response.
Personalized Cancer Vaccine Market Key Takeaways
• By region, North America led the market with highest share of 35% in 2024.
• By type, the dendritic cell segment captured the maximum share in 2024.
• By type, the RNA-based segment is expected to grow at a remarkable CAGR over the forecast period.
• By technology, the cell-based segment led the market with largest share in 2024.
• By technology, the mRNA-based PCV segment is expected to grow at the fastest CAGR from 2025 to 2034.
• By distribution channel, the hospital segment captured the maximum revenue share of 59% in 2024.
Latest Trends in the Personalized Cancer Vaccine Market (2024–2025)
1. Rising Clinical Trials & Pipeline Expansion
• Increasing number of clinical trials for neoantigen-based vaccines, especially in melanoma, NSCLC, and pancreatic cancer.
• Pharma leaders and biotech startups are aggressively expanding pipelines with personalized mRNA cancer vaccines.
2. mRNA-Based Platforms Gaining Dominance
• mRNA vaccine technology (pioneered during COVID-19) is being repurposed and customized for cancer vaccines.
• Companies like Moderna, BioNTech, and partners like Merck are leading in this space.
3. Neoantigen Targeting & Tumor-Specific Approaches
• Focus is shifting from generic tumor antigens to patient-specific neoantigens, improving specificity and immune response.
• AI and bioinformatics are being used to rapidly identify individual tumor mutations for vaccine design.
4. Strategic Collaborations
• Increasing partnerships between biotech firms and big pharma (e.g., Moderna + Merck, BioNTech + Genentech) to develop and commercialize personalized vaccines.
• Collaborations with AI platforms and genomic sequencing firms (e.g., Illumina, Tempus) to accelerate personalization.
5. Regulatory & Reimbursement Landscape Evolving
• Regulatory agencies are beginning to establish special pathways for individualized therapies, including real-time review frameworks.
• Discussions around value-based reimbursement models for highly personalized therapies are gaining traction.
6. Integration with Immunotherapy & Checkpoint Inhibitors
• Personalized cancer vaccines are increasingly being developed as adjuvant therapies with PD-1/PD-L1 inhibitors.
• Goal: Enhance immune response, prevent relapse, and improve long-term survival.
Personalized Cancer Vaccine Market: Major Insights in 2025
|
Category |
Details |
|
Major Applications |
- Melanoma – Most advanced trials; high neoantigen load makes it ideal for personalized approaches. - Lung Cancer (NSCLC) – Large patient base; emerging personalized vaccine trials. - Pancreatic & Colorectal Cancer – Poor prognosis with standard care, high unmet need for personalized immunotherapies. - Triple Negative Breast Cancer (TNBC) – Aggressive subtype; strong immune evasion makes it a good target. - Glioblastoma – Personalized vaccines offer a way around tumor heterogeneity and immune evasion. |
|
Market Potential |
- Projected CAGR: 15–20%+ through 2030. - Market driven by mRNA platform success (e.g., Moderna, BioNTech). - Personalized vaccines expected to become a standard part of cancer immunotherapy regimens. - Expansion into rare and pediatric cancers likely as sequencing costs drop. - Future market estimated to reach multi-billion-dollar valuation as scalability improves. |
|
Key Strategic Drivers |
- Integration with checkpoint inhibitors enhances therapeutic effect and expands use cases. - AI-powered neoantigen prediction reduces development time, increases accuracy. - Fast-track regulatory designations (e.g., Breakthrough Therapy, PRIME in EU) supporting clinical advancement. - Growing patient and physician acceptance of personalized therapies due to better outcomes. - Partnerships between pharma, biotech, and data companies accelerating innovation. |
|
Critical Challenges |
- Manufacturing bottlenecks for individualized therapies (each vaccine must be patient-specific). - High costs pose reimbursement and access hurdles. - Regulatory adaptation needed: Traditional clinical trial models don't suit ultra-personalized therapies. - Data privacy & genomic consent are major ethical and legal considerations. |
|
Regional Momentum |
- United States leading in clinical trials, funding, and partnerships. - Europe investing in public–private partnerships (e.g., Cancer Mission Europe). - Japan & South Korea accelerating personalized cancer programs. - China rapidly scaling NGS and AI platforms for cancer immunotherapy R&D. |
Discover the Full Market Insights 👉
https://www.visionresearchreports.com/personalized-cancer-vaccine-market/41670
Market Opportunity
What is an Opportunity for the Personalized Cancer Vaccine Market?
Expanding Clinical Pipeline and Multi-Cancer Applications An exciting prospect exists in the increasing range of cancer types addressed by PCV candidates. Originally concentrated on melanoma and lung cancer, current trials now encompass breast cancer, pancreatic cancer, glioblastoma, prostate cancer, and also hematologic malignancies. This growth is driven by heightened cooperation between biotech companies and academic research organizations. With increasing genomic mapping of cancers and the identification of immunogenic antigens, the possibility of scalable, platform-based vaccine manufacturing grows, facilitating faster movement from research to clinical settings.
Key Challenges
What is the Limitation for the Personalized Cancer Vaccine Market?
A major difficulty is the elevated expenses linked to the creation and production of these vaccines. The complex procedure of developing a customized vaccine can result in higher costs, hindering broader acceptance, particularly in developing countries. Moreover, regulatory obstacles present another challenge. The intricate approval procedures for new treatments, which frequently necessitate extensive clinical trials and significant data, can postpone the market launch of personalized vaccines.
Personalized Cancer Vaccine Market Report Coverage
|
Report Attribute |
Key Statistics |
|
Market Size in 2025 |
USD 301.90 Million |
|
Market Size in 2026 |
USD 437.45 Million |
|
Market Size in 2030 |
USD 1,928.43 Million |
|
Market Size in 2032 |
USD 4,048.93 Million |
|
Market Size by 2034 |
USD 8,501.14 Million |
|
Growth rate from 2025 to 2034 |
CAGR of 44.9% |
|
Base Year |
2024 |
|
Forecast Period |
2025 to 2034 |
|
Segments Covered |
By Type, By Technology and By Distribution Channel |
|
Companies Covered |
Moderna, Inc., BioNTech SE, Gritstone Bio, Inc., GENCI (Genentech, a member of the Roche Group), Vaccibody AS (now Nykode Therapeutics), EpiVax, Inc., Immunovaccine Inc. (IMV Inc.), Ultimovacs ASA, CEL-SCI Corporation, and Advaxis, Inc. |
For orders or inquiries, don’t hesitate to reach out: sales@visionresearchreports.com
Personalized Cancer Vaccine Market Regional Insights
How North America Dominated the Market?
The personalized cancer vaccine market in North America leads globally, fueled by sophisticated healthcare infrastructure, significant R&D investment, and a rising number of cancer cases. Essential elements driving its expansion encompass advanced tailored medicine strategies, strong governmental programs for immunization, and advancements in mRNA technology. Leading firms are making significant investments to create personalized vaccines that focus on an individual's distinct genetic profile to generate a tailored immune reaction against cancer.
United States: Key Growth Drivers in the Personalized Cancer Vaccine Market
• Leadership in mRNA Vaccine Platforms
The U.S. is home to pioneers like Moderna and BioNTech (U.S.
operations), leading the charge in mRNA-based personalized cancer vaccines.
• Strong R&D Funding and
Infrastructure
High levels of government (e.g., NIH, NCI) and private sector
funding support cancer immunotherapy research, including personalized vaccine
development.
• Active Clinical Trials Ecosystem
The U.S. hosts the largest number of clinical trials for personalized
cancer vaccines, especially in melanoma, lung, and gastrointestinal cancers.
• Regulatory Momentum from the FDA
The FDA is increasingly receptive to individualized treatments, offering
fast-track designations, breakthrough therapy status, and adaptive clinical
trial designs.
• Robust Genomic & Bioinformatics
Capabilities
U.S.-based companies and institutions lead in next-generation sequencing
(NGS), bioinformatics, and neoantigen prediction, critical for vaccine
personalization.
Why is Asia Pacific the Fastest-Growing region in the Market?
Asia Pacific expects the significant growth during the forecast period. Continuous growth relies on the increasing cancer burden in the region, the support of policy for HPV vaccination initiatives, and swift advancements in tailored mRNA–neoantigen technologies. Governments emphasize cervical-cancer prevention, as investors direct funds into biotech hubs that decrease the clinical timelines for novel therapeutic vaccines.
Contract development and manufacturing organizations (CDMOs) in China, India, and South Korea expand production capabilities for viral-vector and mRNA, reducing supply-chain risks and decreasing unit expenses. Collectively, these elements support the double-digit yearly growth of the personalized cancer vaccines market in the Asia-Pacific region.
Japan: Key Growth Drivers in the Personalized Cancer Vaccine Market
• Strong Government Support for Cancer
Immunotherapy
Japan’s Ministry of Health, Labour and Welfare (MHLW) and AMED (Japan Agency
for Medical Research and Development) have prioritized personalized cancer
therapies, offering funding and regulatory guidance for innovative
vaccines.
• Leading Role in Neoantigen Research
Japanese academic institutions (e.g., University of Tokyo, RIKEN, Osaka
University) are advancing neoantigen discovery and personalized vaccine
development, especially in gastrointestinal and liver cancers.
• Clinical Trials in Collaboration with
Global Pharma
Japan is actively participating in global trials, often in partnership with U.S.
and European firms like BioNTech, Moderna, and Merck, to evaluate
mRNA-based cancer vaccines in Asian populations.
• Focus on Solid Tumors Common in Asia
Japanese research focuses on cancers with high regional prevalence, such as gastric,
esophageal, pancreatic, and hepatocellular carcinoma, adapting
personalized vaccines to local disease profiles.
• Robust Genomic Infrastructure
Japan has invested in large-scale national genomic sequencing programs
(e.g., BioBank Japan), supporting precise mutation profiling needed for
personalized vaccine development.
• Advancements in Delivery Technologies
Japanese firms are working on novel delivery systems, including
nanocarriers and lipid nanoparticles, to improve vaccine stability and immune
activation.
Need a Tailored Version of the Report? | Get Customization Options Here: https://www.visionresearchreports.com/report/customization/41670
Personalized Cancer Vaccine Market Segmentation
Type Insights
Why did the Dendritic Cell Segment Dominate the Personalized Cancer Vaccine Market?
The dendritic cell segment dominated the market in 2024, due to DCs' enhanced capacity to deliver tumor antigens to T-cells, initiating a focused immune response against cancer. This efficacy is strengthened by advancements in tailored immunotherapy, regulatory endorsements such as Sipuleucel-T (Provenge), and positive clinical trial results indicating potential in lowering relapse rates and enhancing survival for different cancers, including melanoma, prostate cancer, and acute leukemia. Pharmaceutical and biotechnology firms are significantly investing in DC research, promoting innovation and growth in the sector.
Technology Insights
How the Cell-Based Segment hold the Largest Share in the Personalized Cancer Vaccine Market?
The cell-based segment held the largest revenue share in the personalized cancer vaccine market in 2024, because of its extensive use in dendritic cell vaccines. These vaccines require extracting immune cells from the patient, infusing them with tumor antigens, and reintroducing them to stimulate an immune reaction. Sipuleucel-T (Provenge), the FDA-approved vaccine derived from cells for prostate cancer, opened the door for this category. Even with scalability issues, cell-based technologies continue to be very important, particularly for patients dealing with complex or resistant tumors. They also enable the ex vivo alteration of immune responses, providing exact management of the vaccine's therapeutic capability.
Distribution Channel Insights
How the Hospital Segment hold the Largest Share in the Personalized Cancer Vaccine Market?
The hospital segment held the largest revenue share in the personalized cancer vaccine market in 2024, owing to their crucial function in intricate cancer care, such as accurate administration, immune monitoring, and the combination with chemotherapy and immunotherapy, which necessitates centralized infrastructure, expert personnel, and access to sophisticated diagnostics. Hospitals frequently serve as key locations for clinical trials of innovative cancer vaccines, encompassing both the delivery of the vaccine and the gathering of data for continuous research and development. Patients usually favor undergoing intricate procedures, like customized cancer vaccines, at well-equipped medical facilities such as hospitals.
Browse More Insights:
• Vaccine Market: https://www.visionresearchreports.com/vaccine-market/41731
• Pneumococcal Vaccine Market: https://www.visionresearchreports.com/pneumococcal-vaccine-market/41294
• Vaccine Contract Manufacturing Market: https://www.visionresearchreports.com/vaccine-contract-manufacturing-market/41270
• Dog Vaccine Market: https://www.visionresearchreports.com/dog-vaccine-market/40961
Top Companies in Personalized Cancer Vaccine Market
• Moderna, Inc.
• Gritstone bio, Inc.
• GENCI (Genentech, a member of the Roche Group)
• Vaccibody AS (now Nykode Therapeutics)
• Immunovaccine Inc. (IMV Inc.)
• Ultimovacs ASA
• Advaxis, Inc.
Recent Developments in the Personalized Cancer Vaccine Market
• In March 2025, Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, PhD, Ward-Coleman Chair in Cancer Research and Director of the Vaccine and Cell Therapy Laboratory, have tested a promising new type of personalized multi-peptide neoantigen cancer vaccine, called PGV001, in a small group of patients. This early study (phase 1 trial) is an important step in finding better ways to help people fight cancer.
• In February 2025, Clinical trials of a new personalized mRNA vaccine for cancer therapy are ready to be launched after the successful completion of the volunteer recruitment stage. This was reported by Andrey Kaprin, Director General of the National Medical Research Radiological Centre (NMRRC) of the Ministry of Health of the Russian Federation.
• In February 2025, The Medicines and Healthcare Products Regulatory Agency (MHRA) launched a consultation today on regulatory guidance for individualised mRNA cancer immunotherapies (colloquially referred to as cancer vaccines). This is an important step in bringing promising personalised cancer vaccines closer to clinical practice.
Personalized Cancer Vaccine Market Segmentation
By Type
• Dendritic Cell
• RNA-Based (mRNA)
• Neoantigen-Based
• Tumor-Associated Antigen (TAA) Vaccines
By Technology
• Cell-based
• mRNA PCV
• Others
By Distribution Channel
• Hospitals
• Clinics
• Research & Academic Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Instant Delivery Available | Purchase This Exclusive Research Report Now: https://www.visionresearchreports.com/report/checkout/41670
You can place an order or ask any questions, please feel free to contact at: sales@visionresearchreports.com
About Us
Vision Research Reports is a premier service provider offering strategic market insights and solutions that go beyond traditional surveys. We specialize in actionable market research, delivering in-depth qualitative insights and strategies to global industry leaders and executives, helping them navigate future uncertainties. Our offerings include consulting services, syndicated market studies, and bespoke research reports.
We are committed to excellence in qualitative market research, fostering a team of experts with deep industry knowledge. Our goal is to help clients understand both current and future market trends, empowering them to expand their portfolios and achieve their business objectives with the right guidance.
Web: https://www.visionresearchreports.com
Our Trusted Data Partners
Precedence Research | Statifacts | Nova One Advisor
For Latest Update Follow Us: https://www.linkedin.com/company/vision-research-report
